OncoCyte Corp (OCX)
2.66
-0.12
(-4.30%)
USD |
NASDAQ |
May 03, 16:00
2.69
+0.03
(+1.13%)
After-Hours: 20:00
OncoCyte Gross Profit Margin (Quarterly): -37.26% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -37.26% |
| September 30, 2023 | 57.81% |
| June 30, 2023 | 58.75% |
| March 31, 2023 | 3.37% |
| December 31, 2022 | -9.85% |
| September 30, 2022 | -401.5% |
| June 30, 2022 | 13.08% |
| March 31, 2022 | 65.00% |
| Date | Value |
|---|---|
| December 31, 2021 | -134.1% |
| September 30, 2021 | -88.01% |
| June 30, 2021 | -19.41% |
| March 31, 2021 | 7.03% |
| December 31, 2020 | -42.35% |
| September 30, 2020 | -8.29% |
| June 30, 2020 | -155.2% |
| March 31, 2020 | -981.2% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-981.2%
Minimum
Mar 2020
65.00%
Maximum
Mar 2022
-104.5%
Average
-14.63%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Fonar Corp | 42.89% |
| XWELL Inc | 11.86% |
| ProPhase Labs Inc | -87.34% |
| Applied DNA Sciences Inc | 25.93% |
| Veracyte Inc | 70.09% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -79.90% |
| Return on Assets | -32.54% |
| Return on Invested Capital | -79.90% |
| Profit Margin (Quarterly) | -5.09K% |
| Operating Margin (Quarterly) | -1.61K% |
| Return on Net Operating Assets | -41.52% |